Studies on the epidemiology of Escherichia coli infections. V. Factors influencing acquisition of specific serologic groups.
Stool carrier rates of Escherichia coli serogroups 4, 6, and 75 were determined on admission and discharge for 190 patients. Persons who were in the hospital 3 weeks or longer had an intestinal carrier rate of 46% compared to a rate of 28% in individuals who had no recent hospital contact. Treatment with broad spectrum antibiotics increased the susceptibility for acquisition of certain specific serologic groups. This was apparently not related to replacement of sensitive E. coli by drug-resistant forms. Studies were made to determine the environmental source for colonization of hospitalized patients and the risk of urinary infection in stool carriers of these strains. A survey of inanimate objects of medical and urological wards demonstrated infrequent isolation of 04, 06, and 075, indicating that extraintestinal foci were an unlikely source for hospital-acquired E. coli. Hemagglutination titers with determination of group-specific O antibody failed to demonstrate any deficiency in hospitalized patients who became colonized with certain coliforms. Similarly, no significant deficit in group-specific serum antibody was found in patients who were community carriers of E. coli 04, 06, or 075. Despite a high rate of acquisition of E. coli serogroups 4, 6, and 75 in the stools of hospitalized patients, only those patients undergoing urinary tract manipulation developed bacteriuria.
D000667:Ampicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000906:Antibodies / Q000378:metabolism*; D002512:Cephalothin / Q000627:therapeutic use; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology*; D005243:Feces / Q000032:analysis; D006386:Hemagglutination Tests; D006801:Humans; D007612:Kanamycin / Q000627:therapeutic use; D011113:Polymyxins / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D013444:Sulfisoxazole / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000906:Antibodies; D011113:Polymyxins; D007612:Kanamycin; D013444:Sulfisoxazole; D000667:Ampicillin; D013752:Tetracycline; D002512:Cephalothin; D013307:Streptomycin